Bevacizumab for Central Retinal Vein Occlusion Study

Anders Kvanta

Status and phase: Completed; Phase 3

Conditions: Central Retinal Vein Occlusion

Treatments: Drug: bevacizumab; Drug: Sham bevacizumab injection

Study type: Interventional

Funder types: Other

Identifiers

NCT00906685

ACRVO

Details and patient eligibility

About

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Enrollment: 60 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• CRVO with duration < 6 months
• Visual acuity of 20/800 to 20/50

Exclusion criteria

• CRVO with duration of > 6 months
• previous treatment with anti-angiogenic drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 2 patient groups

Intravitreal bevacizumab

Active Comparator group

Treatment:

Drug: bevacizumab

Sham injection

Sham Comparator group

Treatment:

Drug: Sham bevacizumab injection